MCID: ADL054
MIFTS: 36

Adult Brain Stem Glioma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Adult Brain Stem Glioma

MalaCards integrated aliases for Adult Brain Stem Glioma:

Name: Adult Brain Stem Glioma 12 15 74
Adult Brainstem Neuroglial Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4813
NCIt 51 C9091
UMLS 74 C0278873

Summaries for Adult Brain Stem Glioma

Disease Ontology : 12 A brain stem cancer that is characterized by mass lesion of the brainstem in adulthood, associated cranial nerve nuclei and long tracts, has material basis in abnormally proliferating cells and derives from glial cells.

MalaCards based summary : Adult Brain Stem Glioma, also known as adult brainstem neuroglial tumor, is related to achalasia and neurofibromatosis, type iv, of riccardi. An important gene associated with Adult Brain Stem Glioma is BSG (Basigin (Ok Blood Group)), and among its related pathways/superpathways are Endometrial cancer and Cell surface interactions at the vascular wall. The drugs Fentanyl and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and liver, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Adult Brain Stem Glioma

Diseases in the Brain Stem Glioma family:

Adult Brain Stem Glioma

Diseases related to Adult Brain Stem Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 10, show less)
# Related Disease Score Top Affiliating Genes
1 achalasia 9.9 KIT RET
2 neurofibromatosis, type iv, of riccardi 9.9 KIT RET
3 differentiated thyroid carcinoma 9.9 BSG RET
4 constipation 9.8 KIT RET
5 cerebral primitive neuroectodermal tumor 9.8 BSG SRC
6 waardenburg's syndrome 9.8 KIT RET
7 colonic disease 9.7 RET SRC
8 adenoid cystic carcinoma 9.7 BSG KIT
9 leukemia, chronic myeloid 9.7 KIT SRC
10 myelofibrosis 9.6 KIT SRC

Graphical network of the top 20 diseases related to Adult Brain Stem Glioma:



Diseases related to Adult Brain Stem Glioma

Symptoms & Phenotypes for Adult Brain Stem Glioma

GenomeRNAi Phenotypes related to Adult Brain Stem Glioma according to GeneCards Suite gene sharing:

27 (showing 8, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.9 KIT RET
2 Decreased viability GR00221-A-2 9.9 RET
3 Decreased viability GR00221-A-4 9.9 RET
4 Decreased viability GR00231-A 9.9 RET
5 Decreased viability GR00301-A 9.9 KIT RET SRC
6 Decreased viability GR00402-S-2 9.9 KIT RET SRC
7 Decreased viability in HMC1.1 cells GR00105-A-0 8.96 KIT SRC
8 Increased cell viability after pRB stimulation GR00230-A-1 8.62 KIT RET

MGI Mouse Phenotypes related to Adult Brain Stem Glioma:

47 (showing 7, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.71 BSG KIT RET SRC
2 hematopoietic system MP:0005397 9.67 BSG KIT RET SRC
3 immune system MP:0005387 9.62 BSG KIT RET SRC
4 limbs/digits/tail MP:0005371 9.43 KIT RET SRC
5 neoplasm MP:0002006 9.33 KIT RET SRC
6 reproductive system MP:0005389 9.26 BSG KIT RET SRC
7 respiratory system MP:0005388 8.92 BSG KIT RET SRC

Drugs & Therapeutics for Adult Brain Stem Glioma

Drugs for Adult Brain Stem Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 173, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
3
Dopamine Approved Phase 3,Early Phase 1,Not Applicable 62-31-7, 51-61-6 681
4
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
5 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
6 Narcotics Phase 3
7 Adjuvants, Anesthesia Phase 3
8 Analgesics Phase 3,Phase 2,Phase 1
9 Anesthetics, Intravenous Phase 3
10 Liver Extracts Phase 3,Phase 2,Phase 1
11 Anesthetics, General Phase 3
12 Anesthetics Phase 3
13 Analgesics, Opioid Phase 3
14 Central Nervous System Depressants Phase 3,Phase 2
15 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
16 Cola Phase 3,Phase 1
17 Cholinesterase Inhibitors Phase 3,Phase 2
18 Neurotransmitter Agents Phase 3,Phase 2,Early Phase 1,Not Applicable
19 Nootropic Agents Phase 3,Phase 2
20 Cholinergic Agents Phase 3,Phase 2
21 Central Nervous System Stimulants Phase 3,Phase 2
22 Dopamine Agents Phase 3,Early Phase 1,Not Applicable
23 Dexmethylphenidate Hydrochloride Phase 3
24 Dopamine Uptake Inhibitors Phase 3
25 Neurotransmitter Uptake Inhibitors Phase 3
26
Irinotecan Approved, Investigational Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
27
Bevacizumab Approved, Investigational Phase 2 216974-75-3
28
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
29
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
30
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
31
Carmustine Approved, Investigational Phase 2,Phase 1 154-93-8 2578
32
Iodine Approved, Investigational Phase 1, Phase 2,Phase 2 7553-56-2 807
33
Mercaptopurine Approved Phase 2 50-44-2 667490
34
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
35
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
36
Temozolomide Approved, Investigational Phase 1, Phase 2,Phase 2 85622-93-1 5394
37
Pregabalin Approved, Illicit, Investigational Phase 2 148553-50-8 5486971
38
Levetiracetam Approved, Investigational Phase 2 102767-28-2 441341
39
Sodium Citrate Approved, Investigational Phase 2 68-04-2
40
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
41
Tamoxifen Approved Phase 2 10540-29-1 2733526
42
Aldesleukin Approved Phase 2,Phase 1 110942-02-4, 85898-30-2
43
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
44
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
45
Sargramostim Approved, Investigational Phase 2,Phase 1 123774-72-1, 83869-56-1
46
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
47
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
48
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
49
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
50
Promethazine Approved, Investigational Phase 2 60-87-7 4927
51
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
52
Acetaminophen Approved Phase 2 103-90-2 1983
53
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
54
Lopinavir Approved Phase 2 192725-17-0 92727
55
Calcium Approved, Nutraceutical Phase 2,Phase 1 7440-70-2 271
56
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
57
Veliparib Investigational Phase 1, Phase 2 912444-00-9 11960529
58
Doxil Approved June 1999 Phase 2 31703
59 topoisomerase I inhibitors Phase 2,Phase 1
60 Topoisomerase Inhibitors Phase 2,Phase 1
61 Immunologic Factors Phase 2,Phase 1
62 Angiogenesis Modulating Agents Phase 2,Phase 1
63 Antineoplastic Agents, Immunological Phase 2,Phase 1
64 Angiogenesis Inhibitors Phase 2,Phase 1
65 Immunoglobulins Phase 2,Phase 1
66 Antibodies Phase 2,Phase 1
67 Antibodies, Monoclonal Phase 2,Phase 1
68 Antineoplastic Agents, Alkylating Phase 2,Phase 1
69 Immunosuppressive Agents Phase 2,Phase 1
70 Alkylating Agents Phase 2,Phase 1
71 cadexomer iodine Phase 1, Phase 2,Phase 2
72 Antimetabolites, Antineoplastic Phase 2
73 Nucleic Acid Synthesis Inhibitors Phase 2,Phase 1
74 Antibiotics, Antitubercular Phase 2,Phase 1
75 Anti-Bacterial Agents Phase 2,Phase 1
76 Antimetabolites Phase 2
77 Wakefulness-Promoting Agents Phase 2
78 Cytochrome P-450 CYP3A Inducers Phase 2
79 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
80 Ginkgo Phase 2
81 Anti-Anxiety Agents Phase 2
82 Psychotropic Drugs Phase 2
83 Calcium, Dietary Phase 2,Phase 1
84 Anticonvulsants Phase 2,Phase 1
85 Tranquilizing Agents Phase 2
86 calcium channel blockers Phase 2,Phase 1
87 Hormones Phase 2,Phase 1
88 Estrogen Receptor Modulators Phase 2
89 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Phase 1
90 Hormone Antagonists Phase 2,Phase 1
91 Antineoplastic Agents, Hormonal Phase 2,Phase 1,Not Applicable
92 Estrogen Receptor Antagonists Phase 2
93 Estrogens Phase 2
94 Citrate Phase 2
95 Selective Estrogen Receptor Modulators Phase 2
96 Bone Density Conservation Agents Phase 2,Phase 1
97 Estrogen Antagonists Phase 2
98 Anti-Retroviral Agents Phase 2,Phase 1
99 Antiviral Agents Phase 2,Phase 1
100 Interleukin-2 Phase 2,Phase 1
101 Anti-HIV Agents Phase 2,Phase 1
102 Antirheumatic Agents Phase 2
103 Anti-Infective Agents Phase 2,Phase 1
104 Albumin-Bound Paclitaxel Phase 2,Phase 1
105 Vaccines Phase 2
106 Nutrients Phase 2,Phase 1
107 Micronutrients Phase 2,Phase 1
108 Trace Elements Phase 2,Phase 1
109 BB 1101 Phase 2
110 Anti-Infective Agents, Local Phase 2
111 HIV Protease Inhibitors Phase 2
112
protease inhibitors Phase 2
113 Cytochrome P-450 Enzyme Inhibitors Phase 2
114 Cytochrome P-450 CYP3A Inhibitors Phase 2
115 Adjuvants, Immunologic Phase 2,Phase 1
116
Verteporfin Approved, Investigational Phase 1 129497-78-5
117
Trioxsalen Approved Phase 1 3902-71-4 5585
118
Lomustine Approved, Investigational Phase 1 13010-47-4 3950
119
Vincristine Approved, Investigational Phase 1 2068-78-2, 57-22-7 5978
120
Procarbazine Approved, Investigational Phase 1 671-16-9 4915
121
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
122
Sirolimus Approved, Investigational Phase 1 53123-88-9 46835353 5284616 6436030
123
Everolimus Approved Phase 1 159351-69-6 70789204 6442177
124
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
125
Vinblastine Approved Phase 1 865-21-4 241903 13342
126
Dacarbazine Approved, Investigational Phase 1 4342-03-4 5351166
127
Hydroxyurea Approved Phase 1 127-07-1 3657
128
Docetaxel Approved, Investigational Phase 1 114977-28-5 148124
129
Octreotide Approved, Investigational Phase 1,Not Applicable 83150-76-9 6400441 383414
130
Somatostatin Approved, Investigational Phase 1 38916-34-6, 51110-01-1 53481605
131
Lenalidomide Approved Phase 1 191732-72-6 216326
132
Parathyroid hormone Approved, Investigational Phase 1 9002-64-6
133
Mechlorethamine Approved, Investigational Phase 1 51-75-2 4033
134
Melphalan Approved Phase 1 148-82-3 460612 4053
135
Calcitriol Approved, Nutraceutical Phase 1 32222-06-3 5280453 134070
136
Maleic acid Experimental, Investigational Phase 1 110-17-8, 110-16-7 444972
137
Cediranib Investigational Phase 1 288383-20-0 9933475
138
Vatalanib Investigational Phase 1 212141-54-3 151194
139
Entinostat Investigational Phase 1 209783-80-2
140
Etanidazole Investigational Phase 1 22668-01-5
141 Dihematoporphyrin Ether Phase 1
142 Dermatologic Agents Phase 1
143 Photosensitizing Agents Phase 1
144 Protein Kinase Inhibitors Phase 1
145
Erlotinib Hydrochloride Phase 1 183319-69-9 176871
146 O(6)-benzylguanine Phase 1
147 Antimitotic Agents Phase 1
148 Antineoplastic Agents, Phytogenic Phase 1
149 Vasoconstrictor Agents Phase 1
150 Vitamins Phase 1
151 glucocorticoids Phase 1
152 Analgesics, Non-Narcotic Phase 1
153 Dialysis Solutions Phase 1
154 Mitogens Phase 1
155 Antifungal Agents Phase 1
156 Anthelmintics Phase 1
157 Antimony Sodium Gluconate Phase 1
158 Interferon-alpha Phase 1
159 interferons Phase 1
160 Antiparasitic Agents Phase 1
161 Antiprotozoal Agents Phase 1
162 Interferon alpha-2 Phase 1
163 Imatinib Mesylate Phase 1 220127-57-1 123596
164 Gastrointestinal Agents Phase 1,Not Applicable
165 Radiopharmaceuticals Phase 1,Not Applicable
166 Edotreotide Phase 1,Not Applicable
167 Histone Deacetylase Inhibitors Phase 1
168 Carboxyamido-triazole Phase 1
169 Cariostatic Agents Phase 1,Early Phase 1
170 Fluorides Phase 1,Early Phase 1,Not Applicable
171 Protective Agents Phase 1,Early Phase 1
172 phenylalanine Phase 1
173 Dihydroxyphenylalanine Early Phase 1,Not Applicable

Interventional clinical trials:

(showing 70, show less)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
3 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
4 Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
5 Antineoplaston Therapy in Treating Patients With Brain Stem Glioma Completed NCT00003459 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
6 Irinotecan in Treating Patients With Recurrent Glioma Completed NCT00003134 Phase 2 irinotecan hydrochloride
7 Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma Completed NCT00003616 Phase 1, Phase 2 irinotecan hydrochloride
8 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
9 Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors Completed NCT00002619 Phase 2 carboplatin;thiotepa
10 Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma Completed NCT00003467 Phase 2 carmustine;polifeprosan 20 with carmustine implant
11 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors Completed NCT00003478 Phase 1, Phase 2
12 Carboplatin in Patients With Progressive Gliomas Completed NCT00002749 Phase 2 carboplatin
13 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms Completed NCT00004688 Phase 2 carmustine;mercaptopurine;streptozocin
14 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
15 Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma Completed NCT01026493 Phase 1, Phase 2 temozolomide 60 mg x 21 days;temozolomide 75 mg x 21 days;ABT-888 20 mg x 21 days;ABT-888 40 mg x 21 days;Temozolomide 150 mg x 5 days;ABT-888 40 mg x 5 days
16 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
17 Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors Completed NCT00629889 Phase 2 levetiracetam;pregabalin
18 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
19 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
20 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
21 Talampanel in Treating Patients With Recurrent High-Grade Glioma Completed NCT00064363 Phase 2 talampanel
22 Temozolomide in Treating Patients With Progressive Low-Grade Glioma Completed NCT00003466 Phase 2 temozolomide
23 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
24 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
25 First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/or Radiological Infiltrative Pattern of Progression Not yet recruiting NCT03932981 Phase 2 Temozolomide
26 Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma Terminated NCT01095094 Phase 2 ritonavir;lopinavir
27 Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma Withdrawn NCT00006263 Phase 2 carboplatin;temozolomide
28 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
29 Stereotactic Radiosurgery in Treating Patients With Brain Tumors Completed NCT00019578 Phase 1
30 Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas Completed NCT02186509 Phase 1 Alisertib
31 Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Completed NCT01131234 Phase 1 Gamma-Secretase Inhibitor RO4929097;Cediranib Maleate
32 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
33 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
34 Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma Completed NCT00003876 Phase 1 polifeprosan 20 with carmustine implant
35 O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma Completed NCT00004892 Phase 1 O6-benzylguanine;polifeprosan 20 with carmustine implant
36 Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors Completed NCT00005796 Phase 1 lomustine;procarbazine hydrochloride;vincristine sulfate
37 Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas Completed NCT00003463 Phase 1 carmustine;irinotecan hydrochloride;polifeprosan 20 with carmustine implant
38 Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors Completed NCT00008086 Phase 1 carboplatin
39 Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 Completed NCT01082926 Phase 1
40 A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Completed NCT00784914 Phase 1 temsirolimus
41 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613 Phase 1
42 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1 bortezomib;temozolomide
43 Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine
44 Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma Completed NCT00401024 Phase 1 imatinib mesylate
45 Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma Completed NCT00387933 Phase 1 hydroxyurea;imatinib mesylate;vatalanib
46 CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas Completed NCT00074243 Phase 1 CC-8490
47 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
48 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
49 CC-5013 in Treating Patients With Recurrent Glioma Completed NCT00036894 Phase 1 lenalidomide
50 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
51 Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas Completed NCT00019019 Phase 1 carboxyamidotriazole;paclitaxel
52 Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Completed NCT00003022 Phase 1
53 RO4929097 in Treating Patients With Recurrent Invasive Gliomas Terminated NCT01269411 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097
54 Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors Terminated NCT00110032 Phase 1 EF5
55 Melphalan With BBBD in Treating Patients With Brain Malignancies Terminated NCT00253721 Phase 1 Melphalan
56 Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma Terminated NCT00003567 Phase 1 O6-benzylguanine;carmustine;temozolomide
57 Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom Unknown status NCT00757614
58 DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma Completed NCT00899834
59 Study of Blood and Cheek Cell Samples From Patients With Glioma Completed NCT01009307
60 Study of Tissue Samples From Patients With Glioma or Other Brain Tumors Completed NCT00967200
61 Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial Completed NCT00890435
62 Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors Completed NCT00499798
63 Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders Completed NCT00255671
64 Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma Active, not recruiting NCT01165632 Early Phase 1 fluorine F 18 fluorodopa
65 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas Terminated NCT02175745 Not Applicable 18F-fluoro-dihydroxyphenylalanine
66 Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases Terminated NCT02967380 Not Applicable Gadobenate Dimeglumine;Gadobutrol
67 Yoga Therapy in Treating Patients With Malignant Brain Tumors Terminated NCT01234805 Not Applicable
68 Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy Terminated NCT00471653 temozolomide
69 Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors Withdrawn NCT02194452 Not Applicable
70 Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors Withdrawn NCT00005790 Not Applicable

Search NIH Clinical Center for Adult Brain Stem Glioma

Genetic Tests for Adult Brain Stem Glioma

Anatomical Context for Adult Brain Stem Glioma

MalaCards organs/tissues related to Adult Brain Stem Glioma:

42
Brain, Bone, Liver, Bone Marrow, Kidney, Spinal Cord, T Cells

Publications for Adult Brain Stem Glioma

Variations for Adult Brain Stem Glioma

Expression for Adult Brain Stem Glioma

Search GEO for disease gene expression data for Adult Brain Stem Glioma.

Pathways for Adult Brain Stem Glioma

GO Terms for Adult Brain Stem Glioma

Biological processes related to Adult Brain Stem Glioma according to GeneCards Suite gene sharing:

(showing 18, show less)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.69 KIT RET SRC
2 protein phosphorylation GO:0006468 9.67 KIT RET SRC
3 leukocyte migration GO:0050900 9.58 BSG SRC
4 positive regulation of gene expression GO:0010628 9.58 KIT RET SRC
5 protein autophosphorylation GO:0046777 9.57 KIT SRC
6 homophilic cell adhesion via plasma membrane adhesion molecules GO:0007156 9.56 BSG RET
7 cell differentiation GO:0030154 9.55 RET SRC
8 positive regulation of MAPK cascade GO:0043410 9.54 KIT RET
9 activation of MAPK activity GO:0000187 9.52 KIT RET
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.48 KIT SRC
11 positive regulation of MAP kinase activity GO:0043406 9.43 KIT SRC
12 axon guidance GO:0007411 9.43 BSG RET SRC
13 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.37 KIT SRC
14 peptidyl-tyrosine phosphorylation GO:0018108 9.33 KIT RET SRC
15 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.32 KIT SRC
16 negative regulation of apoptotic process GO:0043066 9.16 SRC
17 positive regulation of protein kinase B signaling GO:0051897 9.13 KIT RET SRC
18 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 8.8 KIT RET SRC

Molecular functions related to Adult Brain Stem Glioma according to GeneCards Suite gene sharing:

(showing 4, show less)
# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.43 KIT RET SRC
2 protein kinase activity GO:0004672 9.33 KIT RET SRC
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.96 KIT RET
4 protein tyrosine kinase activity GO:0004713 8.8 KIT RET SRC

Sources for Adult Brain Stem Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....